The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial
Open accessAbstract
SUMMARY The combination of PD-L1 inhibitor durvalumab and PARP inhibitor olaparib added to standard paclitaxel neoadjuvant chemotherapy (DOP) was investigated in the phase II I-SPY2 trial of stage II/III HER2-negative breast cancer. Seventy-three participants were randomized to DOP and 299 to standard-of-care (paclitaxel) control. DOP increased pathologic complete response (pCR) rates in all HER2-negative (20 to 37%), hormone receptor (HR)-positive/HER2-negative (14% to 28%), and triple negative (TNBC) (27% to 47%). In HR-positive/HER2-negative cancers, MammaPrint ultra-high (MP2) cases benefited selectively from DOP (pCR 64% vs 22%), no benefit was seen in MP1 cancers (pCR 9% vs 10%). Overall,12.3% of patients in DOP arm experienced immune-related grade 3 adverse events vs. 1.3% in control. Gene expression signatures associated with immune response were positively associated with pCR in both arms, while a mast cell signature was associated with non-pCR. DOP has superior efficacy over standard neoadjuvant chemotherapy in HER2-negative breast cancer, particularly in a highly sensitive subset of high-risk HR-positive/HER2-negative patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
Ayers, M., Lunceford, J., Nebozhyn, M., Murphy, E., Loboda, A., Kaufman, D. R., Albright, A., Cheng, J. D., Kang, S. P., Shankaran, V., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci91190 · Cited by 3,788
Pembrolizumab for Early Triple-Negative Breast Cancer
Schmid, P., Cortes, J., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., Denkert, C., Park, Y. H., Hui, R., Harbeck, N., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1910549 · Cited by 3,270
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
Cardoso, F., van’t Veer, L. J., Bogaerts, J., Slaets, L., Viale, G., Delaloge, S., Pierga, J.-Y., Brain, E., Causeret, S., DeLorenzi, M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602253 · Cited by 1,994
Self-citationBayesian Forecasting and Dynamic Models
(1997) · Springer Series in Statistics · doi:10.1007/b98971 · Cited by 1,917
Gene expression markers of Tumor Infiltrating Leukocytes
Danaher, P., Warren, S., Dennis, L., D’Amico, L., White, A., Disis, M. L., Geller, M. A., Odunsi, K., Beechem, J., & Fling, S. P. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0215-8 · Cited by 806
I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy
Barker, A., Sigman, C., Kelloff, G., Hylton, N., Berry, D., & Esserman, L. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.68 · Cited by 766
Self-citationPantelidou, C., Sonzogni, O., De Oliveria Taveira, M., Mehta, A. K., Kothari, A., Wang, D., Visal, T., Li, M. K., Pinto, J., Castrillon, J. A., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1218 · Cited by 743
Symmans, W. F., Wei, C., Gould, R., Yu, X., Zhang, Y., Liu, M., Walls, A., Bousamra, A., Ramineni, M., Sinn, B., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.1010 · Cited by 711
Self-citationNanda, R., Liu, M. C., Yau, C., Shatsky, R., Pusztai, L., Wallace, A., Chien, A. J., Forero-Torres, A., Ellis, E., Han, H., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2019.6650 · Cited by 710
Self-citationLoibl, S., Untch, M., Burchardi, N., Huober, J., Sinn, B. V., Blohmer, J.-U., Grischke, E.-M., Furlanetto, J., Tesch, H., Hanusch, C., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz158 · Cited by 695
Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer
Rugo, H. S., Olopade, O. I., DeMichele, A., Yau, C., van ’t Veer, L. J., Buxton, M. B., Hogarth, M., Hylton, N. M., Paoloni, M., Perlmutter, J., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1513749 · Cited by 554
Self-citationDomchek, S. M., Postel-Vinay, S., Im, S.-A., Park, Y. H., Delord, J.-P., Italiano, A., Alexandre, J., You, B., Bastian, S., Krebs, M. G., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30324-7 · Cited by 484
Rody, A., Holtrich, U., Pusztai, L., Liedtke, C., Gaetje, R., Ruckhaeberle, E., Solbach, C., Hanker, L., Ahr, A., Metzler, D., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2234 · Cited by 460
Self-citationAdaptive Randomization of Neratinib in Early Breast Cancer
Park, J. W., Liu, M. C., Yee, D., Yau, C., van ’t Veer, L. J., Symmans, W. F., Paoloni, M., Perlmutter, J., Hylton, N. M., Hogarth, M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1513750 · Cited by 454
Self-citationImmunotherapy and targeted therapy combinations in metastatic breast cancer
Esteva, F. J., Hubbard-Lucey, V. M., Tang, J., & Pusztai, L. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30026-9 · Cited by 453
Self-citationIdentification and Characterization of MEDI4736, an Antagonistic Anti–PD-L1 Monoclonal Antibody
Stewart, R., Morrow, M., Hammond, S. A., Mulgrew, K., Marcus, D., Poon, E., Watkins, A., Mullins, S., Chodorge, M., Andrews, J., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0191 · Cited by 409
Gianni, L., Huang, C. S., Egle, D., Bermejo, B., Zamagni, C., Thill, M., Anton, A., Zambelli, S., Bianchini, G., Russo, S., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.02.004 · Cited by 396
Sinn, B. V., Fu, C., Lau, R., Litton, J., Tsai, T.-H., Murthy, R., Tam, A., Andreopoulou, E., Gong, Y., Murthy, R., et al. (2019) · npj Breast Cancer · doi:10.1038/s41523-019-0111-0 · Cited by 354
Genomic Index of Sensitivity to Endocrine Therapy for Breast Cancer
Symmans, W. F., Hatzis, C., Sotiriou, C., Andre, F., Peintinger, F., Regitnig, P., Daxenbichler, G., Desmedt, C., Domont, J., Marth, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.4273 · Cited by 282
Self-citationAdaptive clinical trials in oncology
Berry, D. A. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.165 · Cited by 267
Self-citationCombined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors
Peyraud, F., & Italiano, A. (2020) · Cancers · doi:10.3390/cancers12061502 · Cited by 242
Gianni, L., Huang, C., Egle, D., Bermejo, B., Zamagni, C., Thill, M., Antón, A., Zambelli, S., Bianchini, G., Russo, S., et al. (2020) · Cancer Research · doi:10.1158/1538-7445.sabcs19-gs3-04 · Cited by 136
Bridging Different Eras in Sports
Berry, S. M., Reese, C. S., & Larkey, P. D. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474163 · Cited by 106
Self-citationMiles, D. W., Gligorov, J., André, F., Cameron, D., Schneeweiß, A., Barrios, C. H., Xu, B., Wardley, A. M., Kaen, D. L., Andrade, L., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.2243 · Cited by 98
Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib
Daemen, A., Wolf, D. M., Korkola, J. E., Griffith, O. L., Frankum, J. R., Brough, R., Jakkula, L. R., Wang, N. J., Natrajan, R., Reis-Filho, J. S., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2188-0 · Cited by 83
Self-citationWolf, D. M., Yau, C. S. F., Sanil, A. P., Glas, A. M., Petricoin, E. F., Wulfkuhle, J. D., Severson, T., Linn, S. C., Swigart, L. B., Hirst, G. L., et al. (2017) · npj Breast Cancer · doi:10.1038/s41523-017-0025-7 · Cited by 78
Self-citationFoldi, J., Silber, A. L. M., Reisenbichler, E., Singh, K., Fischbach, N. A., Persico, J., Adelson, K. B., Katoch, A., Horowitz, N. R., Lannin, D. R., et al. (2021) · npj Breast Cancer · doi:10.1038/s41523-021-00219-7 · Cited by 72
Self-citationBianchini, G., Pusztai, L., Karn, T., Iwamoto, T., Rody, A., Kelly, C. M., Müller, V., Schmidt, M., Qi, Y., Holtrich, U., et al. (2013) · Breast Cancer Research · doi:10.1186/bcr3481 · Cited by 57
Self-citationCampbell, M. J., Wolf, D. M., Mukhtar, R. A., Tandon, V. J., Yau, C. S. F., Au, A., Baehner, F. L., Veer, L. V., Berry, D. A., & Esserman, L. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0079114 · Cited by 39
Self-citationCombining PARP inhibition with PD-1 inhibitors
Lassen, U. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30509-1 · Cited by 18
Cited by
Breast cancer: pathogenesis and treatments
Xiong, X., Zheng, L.-W., Ding, Y., Chen, Y.-F., Cai, Y.-W., Wang, L.-P., Huang, L., Liu, C.-C., Shao, Z.-M., & Yu, K.-D. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02108-4 · Cited by 958
Yang, F., Xiao, Y., Ding, J.-H., Jin, X., Ma, D., Li, D.-Q., Shi, J.-X., Huang, W., Wang, Y.-P., Jiang, Y.-Z., et al. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2022.09.021 · Cited by 624
Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer
Ye, F., Dewanjee, S., Li, Y., Jha, N. K., Chen, Z.-S., Kumar, A., Vishakha, Behl, T., Jha, S. K., & Tang, H. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01805-y · Cited by 554
Towards targeting the breast cancer immune microenvironment
Harris, M. A., Savas, P., Virassamy, B., O’Malley, M. M. R., Kay, J., Mueller, S. N., Mackay, L. K., Salgado, R., & Loi, S. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-024-00714-6 · Cited by 363
Wolf, D. M., Yau, C., Wulfkuhle, J., Brown-Swigart, L., Gallagher, R. I., Lee, P. R. E., Zhu, Z., Magbanua, M. J., Sayaman, R., O’Grady, N., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.05.005 · Cited by 336
Self-citation
Metadata
- Authors
- Pusztai, L., Yau, C., Wolf, D. M., Han, H. S., Du, L., Wallace, A. M., String-Reasor, E., Boughey, J. C., Chien, A. J., Elias, A. D., Beckwith, H., Nanda, R., Albain, K. S., Clark, A. S., Kemmer, K., Kalinsky, K., Isaacs, C., Thomas, A., Shatsky, R., Helsten, T. L., Forero-Torres, A., Liu, M. C., Brown-Swigart, L., Petricoin, E. F., Wulfkuhle, J. D., Asare, S. M., Wilson, A., Singhrao, R., Sit, L., Hirst, G. L., Berry, S., Sanil, A., Asare, A. L., Matthews, J. B., Perlmutter, J., Melisko, M., Rugo, H. S., Schwab, R. B., Symmans, W. F., Yee, D., van’t Veer, L. J., Hylton, N. M., DeMichele, A. M., Berry, D. A., & Esserman, L. J.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2021-07
- Volume
- 39
- Issue
- 7
- Pages
- 989-998.e5
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W3172174831
- Cited by
- 337
- References
- 31
- FWCI
- 16.83
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.